Androgen receptor moonlighting in the prostate cancer microenvironment
- 1 June 2018
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 25 (6) , R331-R349
Abstract
Androgen receptor (AR) signaling is vital for the normal development of the prostate and is critically involved in prostate cancer (PCa). AR is not only found in epithelial prostate cells but is also expressed in various cells in the PCa-associated stroma, which constitute the tumor microenvironment (TME). In the TME, AR is expressed in fibroblasts, macrophages, lymphocytes and neutrophils. AR expression in the TME was shown to be decreased in higher-grade and metastatic PCa, suggesting that stromal AR plays a protective role against PCa progression. With that, the functionality of AR in stromal cells appears to deviate from the receptor’s classical function as described in PCa cells. However, the biological action of AR in these cells and its effect on cancer progression remains to be fully understood. Here, we systematically review the pathological, genomic and biological literature on AR actions in various subsets of prostate stromal cells and aim to better understand the consequences of AR signaling in the TME in relation to PCa development and progression.Keywords
This publication has 169 references indexed in Scilit:
- Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2‐induced STAT3 activationEMBO Molecular Medicine, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Protumor Activities of the Immune Response: Insights in the Mechanisms of Immunological Shift, Oncotraining, and OncopromotionJournal of Oncology, 2013
- Androgen Receptor Influences on Body Defense System via Modulation of Innate and Adaptive Immune SystemsThe American Journal of Pathology, 2012
- Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro‐inflammatory cytokines/chemokinesEMBO Molecular Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patientsBritish Journal of Cancer, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancerThe Prostate, 2009